PMID- 38272713
OWN - NLM
STAT- MEDLINE
DCOM- 20240318
LR  - 20240318
IS  - 1471-499X (Electronic)
IS  - 1471-4914 (Linking)
VI  - 30
IP  - 3
DP  - 2024 Mar
TI  - Beneath the radar: immune-evasive cell sources for stroke therapy.
PG  - 223-238
LID - S1471-4914(23)00282-4 [pii]
LID - 10.1016/j.molmed.2023.12.004 [doi]
AB  - Stem cell therapy is an emerging treatment paradigm for stroke patients with 
      remaining neurological deficits. While allogeneic cell transplants overcome the 
      manufacturing constraints of autologous grafts, they can be rejected by the 
      recipient's immune system, which identifies foreign cells through the human 
      leukocyte antigen (HLA) system. The heterogeneity of HLA molecules in the human 
      population would require a very high number of cell lines, which may still be 
      inadequate for patients with rare genetic HLAs. Here, we outline key progress in 
      genetic HLA engineering in pluripotent stem and derived cells to evade the host's 
      immune system, reducing the number of allogeneic cell lines required, and examine 
      safety measures explored in both preclinical studies and upcoming clinical 
      trials.
CI  - Copyright (c) 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
FAU - Achon Buil, Beatriz
AU  - Achon Buil B
AD  - Institute for Regenerative Medicine, University of Zurich, Schlieren, 
      Switzerland; Neuroscience Center Zurich, University of Zurich and ETH Zurich, 
      Zurich, Switzerland.
FAU - Rentsch, Nora H
AU  - Rentsch NH
AD  - Institute for Regenerative Medicine, University of Zurich, Schlieren, 
      Switzerland; Neuroscience Center Zurich, University of Zurich and ETH Zurich, 
      Zurich, Switzerland.
FAU - Weber, Rebecca Z
AU  - Weber RZ
AD  - Institute for Regenerative Medicine, University of Zurich, Schlieren, 
      Switzerland; Neuroscience Center Zurich, University of Zurich and ETH Zurich, 
      Zurich, Switzerland.
FAU - Rickenbach, Chiara
AU  - Rickenbach C
AD  - Institute for Regenerative Medicine, University of Zurich, Schlieren, 
      Switzerland; Neuroscience Center Zurich, University of Zurich and ETH Zurich, 
      Zurich, Switzerland.
FAU - Halliday, Stefanie J
AU  - Halliday SJ
AD  - Institute for Regenerative Medicine, University of Zurich, Schlieren, 
      Switzerland; Neuroscience Center Zurich, University of Zurich and ETH Zurich, 
      Zurich, Switzerland.
FAU - Hotta, Akitsu
AU  - Hotta A
AD  - Center for iPS cell Research and Application, Kyoto University, Kyoto, Japan.
FAU - Tackenberg, Christian
AU  - Tackenberg C
AD  - Institute for Regenerative Medicine, University of Zurich, Schlieren, 
      Switzerland; Neuroscience Center Zurich, University of Zurich and ETH Zurich, 
      Zurich, Switzerland.
FAU - Rust, Ruslan
AU  - Rust R
AD  - Institute for Regenerative Medicine, University of Zurich, Schlieren, 
      Switzerland; Neuroscience Center Zurich, University of Zurich and ETH Zurich, 
      Zurich, Switzerland; Department of Physiology and Neuroscience, University of 
      Southern California, Los Angeles, CA, USA; Zilkha Neurogenetic Institute, Keck 
      School of Medicine, University of Southern California, 1501 San Pablo St, Los 
      Angeles, CA, USA. Electronic address: rrust@usc.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240125
PL  - England
TA  - Trends Mol Med
JT  - Trends in molecular medicine
JID - 100966035
SB  - IM
MH  - Humans
MH  - *Induced Pluripotent Stem Cells/metabolism
MH  - Stem Cell Transplantation
MH  - Cell Line
OTO - NOTNLM
OT  - allogeneic stem cell transplantation
OT  - cell therapy
OT  - human leukocyte antigen
OT  - hypoimmunogenic stem cells
OT  - pluripotent stem cells
OT  - stroke
COIS- Declaration of Interests The authors declare no competing interests
EDAT- 2024/01/26 00:43
MHDA- 2024/03/18 06:43
CRDT- 2024/01/25 21:52
PHST- 2023/10/16 00:00 [received]
PHST- 2023/12/04 00:00 [revised]
PHST- 2023/12/06 00:00 [accepted]
PHST- 2024/03/18 06:43 [medline]
PHST- 2024/01/26 00:43 [pubmed]
PHST- 2024/01/25 21:52 [entrez]
AID - S1471-4914(23)00282-4 [pii]
AID - 10.1016/j.molmed.2023.12.004 [doi]
PST - ppublish
SO  - Trends Mol Med. 2024 Mar;30(3):223-238. doi: 10.1016/j.molmed.2023.12.004. Epub 
      2024 Jan 25.